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medication, 13% switched medication, 10% both delayed and stopped medication
while 9% of members both switched and delayed medication. The data show people
who experienced the doughnut hole are 1.3 times more likely to switch, 2 times more
likely to delay, 3 times more likely to switch and delay, and 4.7 times more likely to 
switch, stop, and delay their prescription medications. CONCLUSIONS: The results 
of the study suggest that the doughnut hole is a factor in alteration of prescription 
fulﬁ llment decisions by Part D members. Because patient non-compliance of medica-
tions may result in mortality it is important that the Medicare Part D standard pre-
scription drug plan be designed to limit excessive ﬁ nancial burden to members based
on spending levels.
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OBJECTIVES: This analysis was intended to identify trends in Hormone Replacement 
Therapy (HRT) use in female seniors on public drug programs in 5 Canadian provinces 
between 2001–2002 and 2006–2007. METHODS: Claims level data were analyzed
for female seniors on public drug programs in Alberta, Saskatchewan, Manitoba, New 
Brunswick and Nova Scotia. The analysis included calculation of the proportion of 
female seniors on these programs using HRT, and also examined trends in the dosage
and type of therapy used. RESULTS: The rate of HRT use among female seniors in
the 5 provinces dropped from 13.9% in 2001–2002 to 5.2% in 2006–2007. The
decrease in combination HRT use (24.9% per year) was greater than the decrease in 
estrogen only HRT use (14.7% per year). The vast majority of female seniors still 
using HRT in 2006–2007 were on estrogen-only regimens (84%). Of women using 
the higher (0.625 mg) dose in 2001–2002 and still using HRT in 2006–2007, 37%
had switched to the lower (0.3 mg) dose. CONCLUSIONS: This analysis provides
insight into how new evidence affected HRT use in Canadian female seniors. The 
decline in HRT use observed was consistent with the results of other studies examining 
use during this time period. The majority of women still using HRT at the end of the 
study period were on estrogen-only regimens, with over a third of these women using
a lower dose.
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OBJECTIVES: The purpose of this study was to determine the extent of use, during
pregnancy, of medication(s) containing the active pharmaceutical ingredient(s) (API) 
classiﬁ ed to be teratogenic by the FDA. METHODS: This retrospective study analyzed 
the two 2005 cross-sectional databases of the National Ambulatory Medical Care
Survey (NAMCS) and the outpatient (OPD) section of the National Hospital Ambula-
tory Medical Care Survey (NHAMCS). Pregnant women who were prescribed terato-
genic APIs categorized by FDA as X or D were included in the study. The un-weighted 
data from NAMCS and NHAMCS were used to compute the Chi-square test statistics. 
RESULTS: Of 2,228 pregnancy related ambulatory visits, 22.94% were physician-
ofﬁ ce (PO) visits, and 77.06% were OPD visits. Medications were prescribed during
63.5% of the ambulatory visits. Category-X and/or D APIs were prescribed during
131 of these visits, comprising of 74.81% PO-visits and 25.19% OPD-visits. Chi-
square analysis between the number of visits [when APIs with Risk Categories (X, D, 
and X-and-D) were prescribed] and the trimester was signiﬁ cant (p  0.021) among 
PO-visits, but not signiﬁ cant among OPD-visits. During the PO-visits, Category-D 
APIs were most frequently prescribed in the 3rd trimester, while Category-X APIs were 
only prescribed in the 1st trimester. During the 131 visits, 158 Category-X and/or D 
APIs were prescribed, with 70.9% prescribed during PO-visits, and 29.1% during 
OPD-visits. Chi-square analysis between the number of APIs [with Risk Categories] 
and the trimester, was signiﬁ cant (p  0.025) among OPD-visits but not signiﬁ cant 
among PO-visits. During OPD-visits, the numbers of Category-X and Category-D 
APIs prescribed increased with the progression of the pregnancy. CONCLUSIONS:
This study showed that APIs with teratogenic effect were prescribed to pregnant 
women, particularly during 3rd trimester, with Category-D prescriptions being more 
than that of Category-X. A greater number of Category-D and X prescriptions was 
written during hospital-visits than physician-ofﬁ ce visits.
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OBJECTIVES: We sought to examine racial and ethnic disparities in prescription drug
use among the U.S. older adult population. METHODS: The National, Social life,
Health and Aging Project (NSHAP) was used for this analysis. NSHAP is a nationally 
representative probability sample of 3,005 community-dwelling persons 57 to 85 years
of age from households across the United States. Household interviews were con-
ducted between July 2005 and March 2006. Multivariate logistic regression was used 
to examine the factors associated with differences in prescription medication use 
among non-Hispanic whites (Whites), non-Hispanic blacks (Blacks), and Hispanics
(any race). RESULTS: In unadjusted analyses, in comparison to Whites, the use of at
least one prescription medication was similar in Blacks (odds ratio [OR] 1.15, 95%
conﬁ dence intervals [CI] 0.80, 1.57), but signiﬁ cantly less among Hispanics (OR 0.49, 
CI 0.38, 0.73). After adjusting for demographic and health-related characteristics
including diagnosed medical conditions, Whites were signiﬁ cantly more likely to be 
using a prescription medication than either Blacks (OR 0.68, CI 0.49, 0.94) or Hispan-
ics (OR 0.52, CI 0.37, 0.73). Racial/ethnic disparities for Hispanics were signiﬁ cantly 
reduced (OR 0.73, CI 0.47, 1.14) after accounting for insurance status and usual 
source of care, and racial/ethnic disparities varied by therapeutic drug class. CON-
CLUSIONS: These data provide updated, nationally representative estimates of racial 
and ethnic differences in prescription medication use among community dwelling 
elders. hile differences in demographic and health characteristics did not explain the 
observed disparities in prescription drug use for blacks, socio-economic and access to 
care disparities may. However, differences in access to care were more important for 
Hispanics. In addition, differences in the use of over-the-counter drugs and dietary
supplements is also evident.
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OBJECTIVES: Given the complexity of the Medicare Part D prescription drug beneﬁ t
and annual plan changes, many Medicare beneﬁ ciaries often lack knowledge and skills
needed to select an optimal Part D plan. Through community outreach events targeted
toward underserved populations, we sought to minimize beneﬁ ciaries’ out-of-pocket
(OOP) prescription drug costs. We also examined the relationship between additional 
governmental assistance and potential OOP cost savings. METHODS: Students from 
seven California Schools of Pharmacy were trained to provide one-on-one Part D 
counseling, under faculty supervision. Students obtained the 2009 annual estimated 
costs for each participant’s current stand-alone prescription drug plan (PDP), and 
compared these costs to the lowest-cost plan (if different), using the online Medicare
Prescription Drug Plan Finder tool. Additionally, each participant’s current plan cost
ranking was compared to the 51 PDPs offered in California (2009) and recorded along 
with subsidy status. RESULTS: During 43 statewide outreach events, pharmacy stu-
dents counseled 661 beneﬁ ciaries enrolled in a PDP, of whom 519 (79%) were receiv-
ing governmental assistance with their prescription medication costs (i.e., Medicaid 
or the low-income subsidy). Beneﬁ ciaries were, on average, enrolled in the 12th-
lowest-cost plan (out of 51) in terms of OOP plan costs, and 496 (75%) beneﬁ ciaries 
had potential OOP savings by switching to a lower-cost plan. Those receiving a
subsidy had a lower annual mean OOP potential cost savings than non-subsidized 
beneﬁ ciaries ($399 vs. $587, p  0.0001). However, they had a higher mean percentage
of potential cost-savings relative to the annual cost of their current plan (51% vs. 
32%, p  0.0001). CONCLUSIONS: More than three-fourths of the beneﬁ ciaries in 
this study were not in the PDP with the lowest OOP medications costs. Our data 
suggest that Medicare beneﬁ ciaries, regardless of income, can optimize their prescrip-
tion drug plan choices through outreach interventions conducted by pharmacy stu-
dents with Part D expertise.
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OBJECTIVES: Cost-related nonadherence to prescription drugs (CRN) can result in
unfavorable health conditions. The objective of this study was to examine the relation-
ship between CRN and elements in Part D plan beneﬁ t design. METHODS: This 
was a cross-sectional study using the 2006 Medicare Consumer Assessment of 
Healthcare Providers and Systems (CAHPS) data. We augmented the CAHPS data 
with the Centers for Medicare & Medicaid Services (CMS) plan beneﬁ t design infor-
mation, CMS Hierarchical Condition Category scores and a composite socioeconomic 
indicator derived from U.S. Census data. We examined the relationship using survey
logistic modeling. Our analytic data included survey respondents enrolled in a stand-
alone prescription drug plan (PDP) or Medicare Advantage drug plan (MA-PD) in
2006. Individuals who were identiﬁ ed by CMS as having other creditable drug cover-
age, deemed low-income subsidy, or enrolling in MA cost plans were excluded. 
RESULTS: About one-quarter (weighted percentage) of the study sample (unweighted 
N  133,616; weighted N  11,008,931) was enrolled in an MA-PD. Overall, 24 %
of the sample enrolled in a plan with drug deductibles, 87% had tiered copayments, 
59% were in plans requiring prior authorization or step therapy for eight or more 
of the top 100 drugs, and 94% offered mailorder services. After adjusting for 
other variables, we found MA-PD enrollment was associated with higher reported
CRN compared with PDP enrollment. Additionally, plans with drug deductibles, 
tiered copayments, or mailorder services, were also associated with higher reported 
CRN (OR [95% CI]  1.12 [1.03–1.21], 1.21 [1.04–1.39], 1.24 [1.06–1.46], respec-
tively). Plans requiring prior authorization or step therapy for eight or more of the
top 100 drugs did not present increased risk for CRN. CONCLUSIONS: Medicare 
